Gene info: ID 116519

Gene: APOA5

GENE ID: 116519

Synonyms: APOAV|RAP3

Description: apolipoprotein A5

Gene type: protein-coding

Location: 11q23.3

dbXrefs: Ensembl:ENSG00000110243 MIM:606368 Vega:OTTHUMG00000046116 UniprotKB:Q6Q788

RefSeq: NG_015894.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND|AD

# Publications: 35

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 5.567e-2 (AD) 7.019e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR51G1	0.406
RAG2	0.4
ZC2HC1B	0.391
OR2G2	0.383
PRR9	0.379
OR51A4	0.372
OR56B4	0.371
KRTAP29-1	0.363
OR52Z1	0.353
STRA6	0.35

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
IGSF11	-0.24
OR13C9	-0.238
OXTR	-0.224
CATSPER3	-0.219
PCDHGB1	-0.217
INTU	-0.215
LGR4	-0.207
NKAIN4	-0.206
SCRG1	-0.206
DMRTA1	-0.205

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of APOA5 mRNA"	19114083
C028451	3,4,3',4'-tetrachlorobiphenyl	"3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [Dietary Fats results in increased expression of APOA5 mRNA]"	19467301
D000082	Acetaminophen	Acetaminophen affects the expression of APOA5 mRNA	17562736
D020106	Acrylamide	Acrylamide results in decreased expression of APOA5 mRNA	28959563
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of APOA5 protein	20106945
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of APOA5 mRNA	21641981\|2715375
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of APOA5 gene	27153756
D000638	Amiodarone	Amiodarone results in increased expression of APOA5 mRNA	24489787
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of APOA5 mRNA	16483693
D019324	beta-Naphthoflavone	beta-Naphthoflavone results in decreased expression of APOA5 mRNA	19737606
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of APOA5 mRNA	20106945\|2231617
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of APOA5 mRNA	19770486
D004958	Estradiol	Estradiol results in decreased expression of APOA5 mRNA	20106945
C023888	beta-hexachlorocyclohexane	beta-hexachlorocyclohexane results in decreased expression of APOA5 mRNA	25270620
C006780	bisphenol A	bisphenol A results in decreased expression of APOA5 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased methylation of APOA5 gene	28505145
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide affects the expression of APOA5 mRNA	23410634
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in decreased expression of APOA5 mRNA	25270620
D002994	Clofibrate	Clofibrate results in decreased expression of APOA5 mRNA	17585979
D002994	Clofibrate	Clofibrate results in decreased expression of APOA5 mRNA	12851107
D003024	Clozapine	APOA5 gene polymorphism affects the susceptibility to Clozapine	17726453
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of APOA5 mRNA	24386269
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of APOA5 mRNA	19549813
D016572	Cyclosporine	Cyclosporine results in decreased expression of APOA5 mRNA	20106945\|2556210
C000944	dicrotophos	dicrotophos results in decreased expression of APOA5 mRNA	28302478
D004041	Dietary Fats	"3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [Dietary Fats results in increased expression of APOA5 mRNA]"	19467301
D004041	Dietary Fats	Dietary Fats results in increased expression of APOA5 mRNA	19467301
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of APOA5 mRNA	19245819
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of APOA5 mRNA	15212814
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of APOA5 mRNA	23550701
D058607	Fibric Acids	[Fibric Acids binds to and results in increased activity of PPARA protein] which results in increased activity of APOA5 protein	16511610
D005485	Flutamide	Flutamide results in decreased expression of APOA5 mRNA	24136188
C069837	fullerene C60	fullerene C60 results in decreased expression of APOA5 mRNA	19167457
C039281	furan	furan results in decreased expression of APOA5 mRNA	25539665
C039281	furan	furan results in increased methylation of APOA5 gene	22079235
C004312	glycidol	glycidol results in decreased expression of APOA5 mRNA	24915197
C029424	hydrazine	hydrazine results in increased expression of APOA5 mRNA	15282401
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the expression of APOA5 mRNA	23410634
D007538	Isoniazid	Isoniazid results in decreased expression of APOA5 mRNA	28619387
D007538	Isoniazid	silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA]	28619387
D007538	Isoniazid	[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA	28619387
C052901	lemongrass oil	lemongrass oil affects the expression of APOA5 mRNA	25976427
C482199	lipopolysaccharide, E coli O55-B5	"[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of APOA5 mRNA"	18930950
C051752	nefazodone	nefazodone results in decreased expression of APOA5 mRNA	24136188
C028007	nickel monoxide	nickel monoxide results in decreased expression of APOA5 mRNA	19167457
C012655	nimesulide	nimesulide results in decreased expression of APOA5 mRNA	24136188
C539348	perfluorobutanesulfonic acid	perfluorobutanesulfonic acid results in decreased expression of APOA5 mRNA	21705711
C471071	perfluorohexanesulfonic acid	perfluorohexanesulfonic acid results in increased expression of APOA5 mRNA	23567314
C471071	perfluorohexanesulfonic acid	perfluorohexanesulfonic acid results in decreased expression of APOA5 mRNA	21705711
C479228	perfluorohexanoic acid	perfluorohexanoic acid results in increased expression of APOA5 mRNA	23567314
C101815	perfluoro-n-heptanoic acid	perfluoro-n-heptanoic acid results in increased expression of APOA5 mRNA	23567314
C101816	perfluoro-n-nonanoic acid	perfluoro-n-nonanoic acid results in increased expression of APOA5 mRNA	23567314
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid results in decreased expression of APOA5 mRNA	21705711
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in decreased expression of APOA5 mRNA	19162173
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in increased expression of APOA5 mRNA	23567314
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in decreased expression of APOA5 mRNA	17681415
D010634	Phenobarbital	NR1I3 protein affects the reaction [Phenobarbital results in decreased expression of APOA5 mRNA]	19482888
D010634	Phenobarbital	Phenobarbital results in decreased expression of APOA5 mRNA	19482888\|2527062
C006253	pirinixic acid	[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of APOA5 mRNA	19710929
C006253	pirinixic acid	pirinixic acid results in decreased expression of APOA5 mRNA	15375163\|2081375
C006253	pirinixic acid	pirinixic acid results in increased expression of APOA5 mRNA	18445702
C006253	pirinixic acid	pirinixic acid results in decreased expression of APOA5 mRNA	22484513
D011192	Potassium Dichromate	Potassium Dichromate affects the expression of APOA5 mRNA	23608068
C045950	propiconazole	propiconazole results in decreased expression of APOA5 mRNA	21278054
D054328	Proton Pump Inhibitors	Proton Pump Inhibitors results in decreased expression of APOA5 mRNA	25626140
D011794	Quercetin	Quercetin results in decreased expression of APOA5 mRNA	21632981
C089730	rosiglitazone	rosiglitazone results in decreased expression of APOA5 mRNA	21515302
C440975	silybin	silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA]	28619387
C501413	tesaglitazar	tesaglitazar results in decreased expression of APOA5 mRNA	21515302
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of APOA5 mRNA	22298810
D013749	Tetrachlorodibenzodioxin	AHR protein affects the reaction [Tetrachlorodibenzodioxin results in decreased expression of APOA5 mRNA]	16891777
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in decreased expression of APOA5 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of APOA5 mRNA	16891777\|1879615
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased methylation of APOA5 gene	26756918
D014280	Triglycerides	APOA5 gene SNP affects the abundance of Triglycerides	24097064
C057693	troglitazone	troglitazone results in decreased expression of APOA5 mRNA	21515302
C080163	trovafloxacin	"[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of APOA5 mRNA"	18930950
D014520	Urethane	Urethane results in decreased expression of APOA5 mRNA	28818685
D024483	Vitamin K 3	Vitamin K 3 affects the expression of APOA5 mRNA	23410634
D015215	Zidovudine	silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA]	28619387
D015215	Zidovudine	[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA	28619387
D015215	Zidovudine	Zidovudine results in decreased expression of APOA5 mRNA	28619387

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005543	phospholipid binding	-	IBA	21873635
GO:0005543	phospholipid binding	-	IDA	12810715
GO:0008047	enzyme activator activity	-	IDA	16806135
GO:0008201	heparin binding	-	IDA	15878877 17326667
GO:0008289	lipid binding	-	IDA	12810715
GO:0015485	cholesterol binding	-	IBA	21873635
GO:0017127	cholesterol transporter activity	-	IBA	21873635
GO:0019899	enzyme binding	-	IDA	15178420
GO:0031210	phosphatidylcholine binding	-	IBA	21873635
GO:0031210	phosphatidylcholine binding	-	IDA	16806135
GO:0035473	lipase binding	-	IPI	15178420
GO:0050750	low-density lipoprotein particle receptor binding	-	IPI	17326667
GO:0060228	phosphatidylcholine-sterol O-acyltransferase activator activity	-	IBA	21873635
GO:0060229	lipase activator activity	-	IMP	15178420
GO:0060230	lipoprotein lipase activator activity	-	IDA	18635818
GO:0070325	lipoprotein particle receptor binding	-	IPI	18635818

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0006641	triglyceride metabolic process	-	IDA	11588264
GO:0006641	triglyceride metabolic process	-	IMP	12417525 14729863 17142127
GO:0006695	cholesterol biosynthetic process	-	IBA	21873635
GO:0006869	lipid transport	-	IDA	15178420
GO:0010873	positive regulation of cholesterol esterification	-	IBA	21873635
GO:0010898	positive regulation of triglyceride catabolic process	-	IBA	21873635
GO:0010898	positive regulation of triglyceride catabolic process	-	IDA	18635818
GO:0010902	positive regulation of very-low-density lipoprotein particle remodeling	-	IDA	18635818
GO:0019216	regulation of lipid metabolic process	-	TAS	-
GO:0019433	triglyceride catabolic process	-	IBA	21873635
GO:0019433	triglyceride catabolic process	-	IMP	15178420
GO:0030300	regulation of intestinal cholesterol absorption	-	IBA	21873635
GO:0031102	neuron projection regeneration	-	IBA	21873635
GO:0032374	regulation of cholesterol transport	-	IBA	21873635
GO:0033344	cholesterol efflux	-	IBA	21873635
GO:0033700	phospholipid efflux	-	IBA	21873635
GO:0034370	triglyceride-rich lipoprotein particle remodeling	-	IEA	-
GO:0034372	very-low-density lipoprotein particle remodeling	-	IBA	21873635
GO:0034380	high-density lipoprotein particle assembly	-	IBA	21873635
GO:0042157	lipoprotein metabolic process	-	IBA	21873635
GO:0042246	tissue regeneration	-	IEP	11577099
GO:0042632	cholesterol homeostasis	-	IBA	21873635
GO:0042632	cholesterol homeostasis	-	IDA	19121291
GO:0043687	post-translational protein modification	-	TAS	-
GO:0043691	reverse cholesterol transport	-	IBA	21873635
GO:0044267	cellular protein metabolic process	-	TAS	-
GO:0045723	positive regulation of fatty acid biosynthetic process	-	IBA	21873635
GO:0045723	positive regulation of fatty acid biosynthetic process	-	IDA	18635818
GO:0046470	phosphatidylcholine metabolic process	-	IBA	21873635
GO:0046889	positive regulation of lipid biosynthetic process	-	IBA	21873635
GO:0048260	positive regulation of receptor-mediated endocytosis	-	TAS	18635818
GO:0050996	positive regulation of lipid catabolic process	-	IDA	16806135
GO:0051006	positive regulation of lipoprotein lipase activity	-	IBA	21873635
GO:0051006	positive regulation of lipoprotein lipase activity	-	IDA	15178420 16806135 18635818
GO:0055090	acylglycerol homeostasis	-	IDA	11588264
GO:0055090	acylglycerol homeostasis	-	IMP	15178420
GO:0070328	triglyceride homeostasis	-	IBA	21873635
GO:0070328	triglyceride homeostasis	-	IDA	19121291
GO:0070328	triglyceride homeostasis	-	IMP	18635818

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005576	extracellular region	-	IDA	11577099
GO:0005576	extracellular region	-	TAS	-
GO:0005615	extracellular space	-	IDA	18635818 19121291
GO:0005788	endoplasmic reticulum lumen	-	TAS	-
GO:0034361	very-low-density lipoprotein particle	-	IDA	15528295
GO:0034362	low-density lipoprotein particle	NOT	IDA	15528295
GO:0034364	high-density lipoprotein particle	-	IBA	21873635
GO:0034364	high-density lipoprotein particle	-	IDA	15528295
GO:0042627	chylomicron	-	IBA	21873635
GO:0042627	chylomicron	-	IDA	15528295

KEGG ID	KEGG Term
hsa03320	PPAR signaling pathway

Reactome ID	Reactome Term	Evidence
R-HSA-1430728	Metabolism	TAS
R-HSA-174824	Plasma lipoprotein assembly, remodeling, and clearance	TAS
R-HSA-174824	Plasma lipoprotein assembly, remodeling, and clearance	IEA
R-HSA-1989781	PPARA activates gene expression	TAS
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	TAS
R-HSA-382551	Transport of small molecules	TAS
R-HSA-382551	Transport of small molecules	IEA
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-400206	Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)	TAS
R-HSA-556833	Metabolism of lipids	TAS
R-HSA-597592	Post-translational protein modification	TAS
R-HSA-8957275	Post-translational protein phosphorylation	TAS
R-HSA-8963889	Assembly of active LPL and LIPC lipase complexes	IEA
R-HSA-8963899	Plasma lipoprotein remodeling	TAS
R-HSA-8963899	Plasma lipoprotein remodeling	IEA
R-HSA-8963901	Chylomicron remodeling	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
24402875	Genetic association of lipid metabolism related SNPs with myocardial infarction in the Pakistani population. (2014 Mar)	Iqbal R	Mol Biol Rep
23178747	Overweight modulates APOE and APOA5 alleles on the risk of severe hypertriglyceridemia. (2013 Feb 1)	Lee MJ	Clin Chim Acta
16954607	Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. (2006)	Havasi V	J Mol Neurosci
15177130	Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. (2004 Mar)	Szalai C	Atherosclerosis
20430392	No interaction between alcohol consumption and HDL-related genes on HDL cholesterol levels. (2010 Aug)	Marques-Vidal P	Atherosclerosis
20571505	A single nucleotide polymorphism in APOA5 determines triglyceride levels in Hong Kong and Guangzhou Chinese. (2010 Nov)	Jiang CQ	Eur J Hum Genet
16046221	A genetic variant c.553G > T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population. (2006 Apr)	Tang Y	Atherosclerosis
22407430	Consistency between cross-sectional and longitudinal SNP: blood lipid associations. (2012 Feb)	Costanza MC	Eur J Epidemiol
19185864	Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men. (2009 Aug)	Hyun YJ	Atherosclerosis
28167353	Genetic risk analysis of coronary artery disease in Pakistani subjects using a genetic risk score of 21 variants. (2017 Mar)	Shahid SU	Atherosclerosis
20442857	Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. (2010 Apr 29)	Suchindran S	PLoS Genet
25263629	Increased risk of obesity related to total energy intake with the APOA5-1131T > C polymorphism in Korean premenopausal women. (2014 Oct)	Lim HH	Nutr Res
22460246	Influence of genetic variants in the apolipoprotein A5 and C3 gene on lipids, lipoproteins, and its association with coronary artery disease in Indians. (2010 Sep)	Bhanushali AA	J Community Genet
28102463	Marked Differences of Haplotype Tagging SNP Distribution, Linkage, and Haplotype Profile of APOA5 Gene in Roma Population Samples. (2017 Oct)	Sumegi K	Pathol Oncol Res
21054477	Association of a genetic variant in the apolipoprotein A5 gene with the metabolic syndrome in Chinese. (2011 Feb)	Ong KL	Clin Endocrinol (Oxf)
17766366	Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people. (2008 Jan)	Yamada Y	J Med Genet
19665689	Association between sequence variant of c.553 G > T in the apolipoprotein A5 gene and metabolic syndrome, insulin resistance, and carotid atherosclerosis. (2009 Sep)	Chien KL	Transl Res
18388696	Why study gene-environment interactions? (2008 Apr)	Ordovas JM	Curr Opin Lipidol
21518542	[Association between apolipoprotein A5 gene polymorphism and coronary heart disease in the Han population from Xinjiang]. (2011 Jan)	Yuan S	Zhonghua Liu Xing Bing Xue Za Zhi
19878569	Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. (2009 Oct 30)	Chen SN	BMC Med Genet
16806226	Prediction of genetic risk for metabolic syndrome. (2007 Apr)	Yamada Y	Atherosclerosis
18577813	Apolipoprotein A5 gene IVS3+G476A allelic variant confers susceptibility for development of ischemic stroke. (2008 Jul)	Maasz A	Circ J
27827461	Association and interaction of APOA5, BUD13, CETP, LIPA and health-related behavior with metabolic syndrome in a Taiwanese population. (2016 Nov 9)	Lin E	Sci Rep
26387083	Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease: a case-control and meta-analysis study. (2015 Sep 19)	Yang G	Lipids Health Dis
29310573	Association of rs662799 in APOA5 with CAD in Chinese Han population. (2018 Jan 8)	Chen H	BMC Cardiovasc Disord
19107359	Polymorphism of apolipoprotein A5 is a risk factor for cerebral infarction in type 2 diabetes. (2008 Dec)	Li X	J Huazhong Univ Sci Technolog Med Sci
19055447	Apolipoprotein A5 gene -1131T/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan. (2008)	Hsu LA	Clin Chem Lab Med
18274806	Apolipoprotein A5 gene C56G variant confers risk for the development of large-vessel associated ischemic stroke. (2008 May)	Maasz A	J Neurol
26824674	Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome. (2016)	Wu Y	PLoS One
21287515	[Association of apolipoprotein A5 gene polymorphism with coronary heart disease in Uygur population of Xinjiang]. (2011 Feb)	Yuan S	Zhonghua Yi Xue Yi Chuan Xue Za Zhi
20303129	Contribution of APOA5-1131C allele to the increased susceptibility of diabetes mellitus in association with higher triglyceride in Korean women. (2010 Nov)	Lee KH	Metabolism
18087544	[Study on polymorphism in the apolipoprotein A5 gene in patients with premature coronary heart disease]. (2007 Dec 18)	Yu Y	Beijing Da Xue Xue Bao Yi Xue Ban
20429872	Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study. (2010 Apr 29)	Ariza MJ	BMC Med Genet
28128572	[Genetic determination of dyslipidemia - What tell us the results of genome-wide association studies?] (Fall 2016)	Hubacek JA	Vnitr Lek
22333545	[Distributional characteristics of apolipoprotein A5 Gene c.553G > T polymorphism and association with serum triglyceride in healthy Chinese Han and Uighur people]. (2011 Nov 1)	Abulizi A	Zhonghua Yi Xue Za Zhi